Navigation Links
The Leukemia & Lymphoma Society to Fund Research Focused on Long-Term and Late Effects of Cancer Treatment
Date:9/14/2009

WHITE PLAINS, N.Y., Sept. 14 /PRNewswire/ -- The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.

While research continues to seek new safe and effective drugs, what patients need now is for current therapies to be made less harmful without sacrificing their effectiveness.

In a new initiative, The Leukemia & Lymphoma Society (LLS) will invest in research designed to discover the biological mechanisms that cause late effects, and to develop and test measures to prevent or at least significantly reduce toxicities. LLS is seeking requests for proposals from scientists studying these issues. ( http://www.leukemia-lymphoma.org/graphics/National/QualityofLifeResearchFundingOpportunity.pdf)

The pediatric cancer story has shown us that the goal is achievable. Years of research and clinical trials enabled survival rates to reach nearly 90% for children with acute lymphocytic leukemia. But then the medical and research community recognized that the serious late effects were severely impacting quality of life. High-dose radiation treatments, once thought critical to cures, have been eliminated for most children, significantly reducing cognitive deficits and other once common side-effects.

Now LLS has set a goal of doing for all cancer patients, regardless of age, what has been achieved for many children -- survival with good quality of life.

The initiative is being led by Anna T. Meadows, M.D., medical director of the Cancer Survivorship and Living Well After Cancer Program at the Children's Hospital of Philadelphia. Dr. Meadows is an internationally recognized pioneer in late effects research; she helped quantify the serious consequences of high-dose radiation and eliminate it from curative treatments for most children with leukemia and lymphoma.

"We must find the answers and test them as soon as possible," says Dr. Meadows. "We must be determined and courageous -- funders, researchers, and patients alike -- because survival is just the first part of the struggle to cure cancer; the quality of that survival matters."

To learn more about the LLS Quality of Life Funding Initiative, visit http://www.leukemia-lymphoma.org/graphics/National/QualityofLifeResearchFundingOpportunity.pdf

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

    Contact: Andrea Greif
    (914) 821-8958
    andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
6. Mutant Genes in High-Risk Childhood Leukemias Identified
7. Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
8. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
9. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):